Pharmaceutical Market Of Ukraine Research Articles

Marketing research of the range of medicinal products based on salts of natural origin

As a source of supply of a balanced complex of salts in pharmaceutical practice, sea water (MW), sea salt (MS), obtained by the method of ordinary evaporation, or salt solutions made from standardized raw materials are used. Deep seawater (SW), typically pumped from depths greater than 200 m, contains a wealth of trace elements, including magnesium, calcium, potassium, chromium, selenium, zinc, and vanadium. Due to this, SW has the potential of a source and raw material for the creation of medicinal products for human health.
 The purpose of the work was to research the assortment of preparations based on salts of natural origin and analyze the segment of such products on the pharmaceutical market of Ukraine as of June 2022.
 The research was conducted on the basis of data from the State Register of Medicinal Products of Ukraine, the Morion information search program, and the classification system of the ATS electronic resource Compendium.online. Methods of structural, statistical and graphic analysis were applied in the work, and their generalization and systematization was carried out.
 It was established that on the pharmaceutical market of Ukraine, the segment of medicines, medical products and cosmetics, the source of active substances of which is SW and/or SS, is represented by 150 trade names. It was determined that by type of registration, the most common are medical products (51%) and cosmetics (42%), only 7% of registered drugs are registered. Manufacturers use sea water obtained from the deep water basins of the Adriatic, Aegean, Mediterranean Seas, Atlantic Ocean, Kankal Bay, sea water of Gullmarsfjorden. Domestically produced drugs of the investigated market segment occupy a share of 57%. Among the importing countries, the leaders are Croatia (9%) and Poland (5%). The analysis of the nomenclature established that the most common medicinal form of the drugs are nasal sprays (78%).
 The obtained data show that as the active substance of saline solutions, manufacturers declare SS (56% of the nomenclature) and SW (53%), however, not all products contain information about the source of origin of SS/SW. It was determined that there are no products on the pharmaceutical market of Ukraine based on the SW and SS of the Black and Azov seas, which is the basis for research and the creation of new drugs of domestic production.

Retrospective research of the range of combined antihypertensive drugs in Ukraine in 2022 compared to 2015

The prevalence of arterial hypertension is reaching alarming proportions in low- and middle-income countries, including Ukraine. A sufficiently high prevalence of hypertension among people of the working age creates an additional economic burden on the country's budget.
 Domestic and international clinical guidelines for the treatment of hypertension recommend to prefer using the combinations of drugs from different groups for the treatment of hypertension. Fixed combinations provide additional benefits for patients and healthcare programs, including simpler dosing regimens, improved adherence and better blood pressure control.
 The aim of this research was to analyze the dynamics of changes in the range of fixed combinations of antihypertensive drugs registered at the pharmaceutical market of Ukraine in 2022 compared to 2015.
 The object of the research was the data of the State Register of Medicinal Products of Ukraine for 2015 and 2022. The research was conducted using modern methods of analysis, systematization and generalization, mathematical and statistical calculations.
 According to the results of the retrospective analysis it was established that the total number of registered drugs increased by 28%. During the analyzed period, the assortment of the domestic market was supplemented with new combinations of antihypertensive drugs, which contribute to the qualitative and quantitative expansion of the assortment of combined antihypertensive drugs.
 In the analyzed period, there was a tendency to increase the share of medicines containing a fixed triple combination of active substances, which have antihypertensive effect, from 5.8% in 2015 to 13.6% of the assortment in 2022.
 The analysis of the assortment structure of combined antihypertensive drugs made it possible to establish a significant dominance of two groups, namely, angiotensin II receptor blockers in combination with diuretics (almost 27% of the assortment) and angiotensin-converting enzyme inhibitor with diuretics (from 36.1% to 20% of the assortment).
 According to the analysis, the dominance of foreign medicines at the pharmaceutical market of Ukraine was established. In 2015, the share of Ukrainian manufacturers was 26.45%, but the expansion of the range of drugs in the period until 2022 was provided by foreign manufacturing companies, which led to decrease in the share of domestic drugs to 17.3%.
 The analysis of the domestic market of combined antihypertensive drugs showed significant saturation and increase in the depth of the product range in the period to 2022. Nevertheless, it also made possible to establish the feasibility of creating and developing domestic combined antihypertensive drugs.

Analysis of oral hypoglycemic drugs that are subject to reimbursement in Ukraine

Increasing the affordability of pharmaceutical provision to the population is the most important task of the governments, especially in the context of health care reform. Therefore, considering that reimbursement of the cost of drugs increases their affordability, it is relevant to analyze the updated list of GLDs that are subject to reimbursement.
 The purpose of the work is to conduct an audit of oral GLDs for the treatment of type 2 diabetes, which are subject to reimbursement under the state program in Ukraine, and to study their affordability.
 The objects of the research were the State Register of Medicinal Products, the Register of Maximum Wholesale and Retail Prices for Drugs, which are subject to reimbursement under the program of state guarantees of medical care for the population. Bibliosemantic, marketing, analytical, graphical, generalizing analyzes and mathematical calculations were used.
 An audit was conducted of GLDs, except of insulin, for the treatment of patients with type 2 diabetes, the cost of which is subject to reimbursement under the program under the state guarantee program. Only three drugs under the INN are subject to reimbursement: metformin, glibenclamide, and gliclazide. The number of TNs is 51 Ukrainian-made and foreign-made GLDs, and the majority (76.9%) are domestic products. Metformin, gliclazide, and glibenclamide tablets are available in a sufficient assortment of 40 TN, 8 TN, and 3 TN tablets, respectively, in different dosages and packaging (No 30, No 60, No 90, No 120). There are no prolonged forms of metformin, although they are available on the pharmaceutical market of Ukraine. 3 glibenclamide drugs, 1 drug out of 8 – gliclazide, and 13 out of 40 drugs – metformin are subject to full reimbursement. Others require co-payments from the patient. Calculations of co-payments DDD of GLDs that are partially reimbursable, taking into account dosage and packaging, have been carried out. The co-payments for DDD ranges from UAH 0.111 to UAH 2.510 for gliclazide, and from UAH 0.105 to UAH 1.576 for metformin. The co-payments for foreign-made drugs is more than that of the domestic one.
 To increase the affordability of GLDs and the introduction of modern treatment schemes, it is necessary to expand the list of reimbursable GLDs, including prolonged forms of metformin and innovative drugs. Innovative drugs such as GLP1 and SGLT2 are recommended to be used at the beginning of treatment to prevent the development of DM complications.

Review of pharmacotherapeutic properties of crataegus sanquinea and its medicines

The species of redhaw hawthorn and its raw material, including fruits, as a plant raw material was characterized. Biological stocks of raw materials in Ukraine and alternative possibilities were summarized. It has been found that the majority of hawthorn species growing in Ukraine have very similar chemical compositions and therefore can be interchangeable.
 The chemical composition was analysed, a full list of biologically active substances of hawthorn fruits was given and their influence on biological processes was characterized. The process of preparation, drying, and storage of medicinal raw materials is also described in detail.
 The assortment of medicines in the pharmaceutical market of Ukraine, which contains their composition of hawthorn fruits, was analysed.
 It is established that the official list of drugs has 26 names, but in traditional medicine and unofficial sources, these drugs are far greater.
 It has been revealed available both single- and multicomponent medicinal drugs are presented in different dosage forms.
 The directions of application of hawthorn fruits for therapeutic purposes in various ailments are described, the ways of their use are given, and contraindications for use and peculiarities of preparation and use of various dosage forms are characterized in detail.

Aspects of the retinoid use in the pharmaceutical practice

Aim. To analyze the use of retinoids in the pharmaceutical practice of Ukraine and the world and determine the prospects for the development of domestic medicinal products containing retinoids.
 Materials and methods. The study objects were local and systemic medicines containing active substances belonging to retinoids by their composition (adapalen, tazarotene, tretinoin, acitretin, isotretinoin, etc.). For the analysis of the recent research and publications the methods of scientific analysis were used; they contributed to the comparison, analysis, generalization and systematization of literature data. To achieve the goal, generally accepted research methods were used; they contributed to an objective assessment of the analysis of the pharmaceutical market.
 Results. Based on the results of the studies conducted, a brief description and classification by generations of the group of active substances belonging to retinoids is given. The list of diseases for which these substances are used in world therapeutic practice has been determined. Data regarding the need to use modern techniques to preserve the therapeutic properties of retinoids have been obtained. The pharmaceutical market of Ukraine has been studied for the presence of medicinal products containing retinoids (6 products of local action out of the range of only 9 products). Dosage forms (gels and lotions) for the treatment of dermatological diseases in Ukraine have been identified. It has been found that adapalene has a greater share of medicines at the pharmaceutical market of Ukraine as local agents.
 Conclusions. The studies have shown the absence of domestic medicinal products containing retinoids for the treatment of a number of dermatological diseases at the pharmaceutical market of Ukraine. Based on the research results, the relevance of further studies on the development of retinoid-containing products for use as local therapy has been determined.

Segmentation of modern dosage forms at the pharmaceutical market of Ukraine

In the current conditions of the pharmaceutical industry development the segmentation of available dosage forms among 13898 medicines registered on the territory of Ukraine allows to optimize the pharmaceutical provision of the population. Aim. To comprehensively analyze medicines registered in Ukraine. Materials and methods. The study material was data of the State Register of Medicines of Ukraine in 2022. The research methods used were frequency and content analysis. Results and discussion. As a result of the content analysis, it has been found that the pharmaceutical market of Ukraine is represented by 13898 items of medicines; among them 10965 are ready-made medicinal products (78.89 %) and 2146 are substances (15.44 %), where the largest share is made up of finished dosage forms, namelysolid dosage forms: tablets (49.96 %), solutions (17.17 %), capsules (10.37 %) and powders (10.01 %) with a preference for foreign production of 66.35 %. Medicines in the form of capsules and their varieties with the advantage of foreign production of 76.01 % of trade names are also determined. Conclusions. As a result of the content analysis, the range of dosage forms registered on the territory of Ukraine amounting to 13898 trade names has been determined. Solid dosage forms (tablets, capsules) account for 6617 trade names and occupy 60.35 % of the pharmaceutical market of Ukraine. When analyzing manufacturers of modern dosage forms it has been found that the ratio of capsules of foreign and domestic production is 2:1, where Indian dosageforms make up 18.54 %.

Impact of reimbursement program “Аffordable Medicines” on consumptiom of beta-blockers in Ukraine in 2017-2020

Abstract: the article presents the results of the study of impact of the reimbursement program “Affordable medicines” on consumption of beta-blockers in Ukraine, used for treatment of cardiovascular diseases. Analysis was conducted based on analytical data of Ukrainian pharmaceutical market research system “PharmXplorer” of the company “Proxima Research”, with current legislation taken into account. It was estimated, that in 2021, according to international non-proprietary name and 5th level of ATC classification - two non-selective beta-blockers: propanolol (ATC code С07АА05) and sotalol (С07АА07); six selective beta-blockers: metoprolol (С07АВ02), atenolol (С07АВ03), betaxolol (С07АВ05), bisoprolol (С07АВ07), esmolol (С07АВ09) and nebivolol (С07АВ12); and one beta-blocker from alpha and beta blocking agents group – carvedilol (C07GA02) are allowed for medical use in Ukraine. From the beginning, when reimbursement program “Affordable medicines” was implemented (April 1st, 2017), only 4 beta-blockers were included in the reimbursement list. Consumption patterns were analyzed in terms of defined daily dose, and it was estimated that bisoprolol was the leader among all beta-blockers in terms of consumption in period from 2016 to 2020. The findings show, that among beta-blockers, that were included in the reimbursement list, the major annual growth of consumption was detected for bisoprolol and carvedilol, although the growth of consumption of metoprolol and atenolol was noted only within the first year of functioning of the reimbursement program “Affordable medicines”, and beginning from 2018, the consumption of these two beta-blockers was declining annually. Among beta-blockers, that were not included in the reimbursement list, the increase in annual growth of consumption was spotted for nebivolol and sotalol. DDD/1000 inhabitants/day indicators were calculated for each beta-blocker. It was found, that throughout the years the biggest value of this indicator was for bisoprolol – 8,46 in 2016; 11,74 in 2017; 15,28 in 2018 ; 16,88 and 17,48 in 2019 and in 2020 respectfully. The growth of this indicator can give evidence about positive effect of the reimbursement program “Affordable medicines” on consumption of bisoprolol and its affordability for population in Ukraine in 2017-2020.

THE MARKETING ANALYSIS OF MEDICINES CONTAINING INULIN AND PRESENTED AT THE PHARMACEUTICAL MARKET OF UKRAINE

Medicines containing inulin and which are registered on the pharmaceutical market of Ukraine have been studied. A comparative analysis of drugs by characteristics: country of manufacture, dosage form, composition. It is proposed to carry out extensive information work among medical and pharmaceutical specialists regarding the use of inulin-containing phytoremedies.

Consumption analysis of two-component fixed combinations of medicines for arterial hypertension treatment in Ukraine as one of the stages for evaluation of their reimbursement prospects

The aim was to conduct a retrospective consumption analysis of 4 groups of single pill combinations for hypertension treatment and identify potential candidates for future inclusion in the reimbursement list in Ukraine, based on retrospective consumption patterns.
 Materials and methods: The objects of the study were retail sales data in pharmaceutical market in Ukraine of four groups of single pill combinations used for arterial hypertension treatment. Data was provided by the marker research system “Pharmstandard” of the company of “Morion”. Analytic-comparative, systematic, logical, and mathematical-statistical methods were used.
 Results: Single pill combinations of ACE inhibitors with diuretics were the most consumed among other combinations on 2018-2020. Retrospective evaluation of consumption patterns in period of 2018-2020 showed that combinations of captopril and hydrochlorothiazide (HCTD) 50 mg/25 mg, enalapril and HCTD 10 mg/25 mg, lisinopril and HCTD 10 mg/12.5 mg were the most consumed. Among ARB and diuretics combinations valsartan and HTCD (160 mg/12.5 mg and 80 mg/12.5 mg) and losartan and HTCD (50 mg /12.5 mg) were the most consumed among ARB and diuretics combinations. Within ACE inhibitors and calcium channel blockers (CCB) combinations the most consumed were lisinopril/amlodipine 10 mg/5 mg and a perindopril arginine/amlodipine 5 mg/5 mg. Valsartan and amlodipine holds the majority among ARC and CCB combinations, consumed in period of 2018-2020.
 Conclusion: Apart from the single pill combinations, enlisted in the WHO Essential medicines list, eight more single pill combination were identified, based on retrospective consumption patterns, as potential candidates for further inclusion in the reimbursement list in Ukraine

Antiseptics: analysis of assortment, technologies of compounding and using

Proper hand hygiene disrupts the spread of a numerous infections and is therefore a guarantee of good human health. Wide use of antiseptics by the public raises questions about their effectiveness, safety and availability. At the same time, the culture of hand hygiene is a priority for all spheres of society.
 The aim of the work is to study the range of antiseptics on the pharmaceutical market of Ukraine and assess the peculiarities of their use, to compound the antiseptic for hands of optimal composition and provide its quality control.
 The study used information retrieval, pharmacological, organoleptic, physical and chemical, graphic and statistical methods.
 Based on the analysis of information sources, the active ingredients and their optimal concentrations in the composition of antiseptics of industrial and extemporaneous production have been established. According to the results of this stage of work, four prescriptions of antisepticswith different compositions were selected for further compounding.It was found that positive results of quality control according to the organoleptic and physical and chemical parameters were received for the solution compounded using 96%ethanol and paying attention to key technological features that are decisive in the compounding of non-aqueous solutions and affect the quality of the product.
 The problematic issues of registration and circulation of antiseptics in Ukraine were identified as a result of the development of normative documents. Its consequence is the spread of unscrupulous practices of selling products that do not have a proven disinfection effect. The active components of industrial and extemporaneous antiseptic agents were determined based on the analysis of literary sources. It was established that most of the products recommended for home production did not meet the requirements of regulatory documents in terms of composition and concentration of active substances. This is a sign of the spread of unreliable information among the population, which can harm health. The need to comply with the rules for dosing ingredients and the technological features of manufacturing of non-aqueous solutions is substantiated. It was established that the required concentration of ethanol in the finished product is achieved when preparing solutions according to prescription N 3, which included 96% ethanol according to the results of the physical and chemical control. The presence of disinfection corners at National Pirogov Memorial Medical University, Vinnytsya certainly popularizes hand hygiene among students of higher education. This is indicated by the high frequency of students' use of the products that were placed in the appropriate places. At the same time, it was established the need to conduct educational work among students, which will contribute to increasing the level of awareness of the regulatory framework of registered disinfectants, their proper composition, labeling and method of use.

Modern ways of doxicycline delivery and prospects of application in pharmacy

Currently, the global increase in resistance of pathogens to widely used antibiotics requires a return to the practice of using some classic drugs with preserved activity, finding new ways and directions of delivery of antibiotics to the locations of pathogenic microorganisms and the use of antimicrobial drugs that are not yet resistant. Doxycycline refers to antimicrobial drugs that do not yet have widespread resistance. Numerous studies of doxycycline have now been described as enhancing therapeutic effects, including COVID-19-related diseases, and finding new delivery routes to limit systemic side effects associated with high doses and avoid antibiotic resistance.
 The aim of the work was to analyze modern ways of doxycycline delivery, to determine the prospects for use in pharmacy, to summarize and systematize data on its functional purpose in the development of drugs with specified pharmaco-technological parameters.
 It is established that in the Ukrainian pharmaceutical market the range of drugs based on doxycycline hyclate is represented only by solid oral dosage forms - tablets and capsules for immediate release, but in the global pharmaceutical market there are additional dosage forms that provide parenteral delivery of doxycycline and oral forms. suspensions, syrups, dispersed tablets and delayed-release dosage forms – tablets, capsules and granules, which are the basis for the development of domestic drugs based on doxycycline.
 Development of new dosage forms with modified DH, such as implants, aerosols, lyophilisate for solution for injection, development of new manufacturing technologies, selection of excipients and delivery systems can improve the pharmacological action of antibiotics by reducing the dose and frequency of administration, prolonged or controlled programming. , and expanding the range of therapeutic action.
 Doxycycline is promising in pharmaceutical practice for the treatment of COVID-19, both due to its ability to inhibit matrix metalloproteinases (MMPs) and antiviral activity, especially against Mycoplasma pneumoniae, which is a secondary bacterial cause of pneumonia during the COVID-19 pandemic.

PROSTATE CANCER AND HIS INFLUENCE ON REPRODUCTIVE HEALTH

The aim of the study. Based on the data of the National Cancer Registry the research aims at conducting an analysis of morbidity and mortality of the male population of Ukraine for prostate cancer from 2014 to 2019.
 Materials and Methods. We have studied the indicators of the proportion of malignant neoplasms of the pelvic organs among the ten main nosological forms of malignant neoplasms in the morbidity of the male population of Ukraine, the proportion of malignant neoplasms of the pelvic organs among the ten major nosological forms of malignant neoplasms in the mortality of male malignancies in Ukraine, mortality from malignant neoplasms of the prostate in Ukraine and the percentage of morphologically and histologically confirmed cases of malignant neoplasms of the prostate in Ukraine in the period from 2014 to 2019.
 Results and Discussion. Among the ten main nosological forms of malignant neoplasms in the structure of the incidence of malignant neoplasms in the male population, the share of diseases of malignant neoplasms of the prostate in 2019 is 12.4%. The proportion of malignant neoplasms of the prostate in the mortality structure of the male population of Ukraine from 2014 to 2019 increased from 8.3% to 9.7%, respectively, while the proportion of malignant neoplasms of the rectum and bladder were in some years higher or equal to 2019. The absolute number of cases of malignant neoplasms of the prostate from 2014 to 2019 increased from 6851 cases to 8178 cases, i.e. by 1327 cases, which is 16.23%. Mortality of the male population of Ukraine from malignant neoplasms of the prostate from 2014 to 2019 fluctuated, with an increase in 2017 and a decrease in 2018, but the mortality rate increased from 3119 cases in 2014 to 3323 cases in 2019. The average percentage of morphologically confirmed cases of malignant neoplasms of the prostate was 90.6±0.81%, and the average percentage of histologically confirmed cases of malignant neoplasms of the prostate was 83.57±1.06. Correlation-regression analysis of the growth of the incidence of malignant neoplasms of the prostate in Ukraine for the next 5 years showed that the number of cases will increase significantly but will not exceed 10,000 cases. Correlation-regression analysis of the growth of mortality from malignant neoplasms of the prostate in Ukraine for the next 5 years showed that by 2024 mortality from this pathology will reach almost 3,500 cases per year.
 Conclusions. The obtained data indicate a clear trend towards an increase in morbidity and mortality from malignant neoplasms of the prostate. Among the main factors that may influence this are the low level of vaccination of male and female population of Ukraine from highly oncogenic strains of human papillomavirus, lack of motivation of the male population of Ukraine to a comprehensive screening of the prostate after 45 years and low awareness of the need for such screening, availability of three-component vaccines against human papillomavirus on the pharmaceutical market of Ukraine, while vaccination with seven-component vaccines against this virus is routine in the European Union. Further research on the coverage of the male population with vaccination and on the awareness of the male population of Ukraine about the risks of prostate cancer is necessary in terms of preventing reproductive dysfunction and the proper formation of reproductive health in general.

АНАЛІЗ АСОРТИМЕНТУ АНТИБАКТЕРІАЛЬНИХ ЗАСОБІВ ДЛЯ СИСТЕМНОГО ЗАСТОСУВАННЯ ФАРМАЦЕВТИЧНОГО РИНКУ УКРАЇНИ

The presented work demonstrates the results of the analysis of data from official sources of information on the range of antibacterial agents for the systematize the use of available in the pharmaceutical market of Ukraine. It is established that the total number of drugs of this group is 972 units, the largest subgroup is J01D Other β-lactam antibiotics (384 units); the form of release is dominated by powders of 427 items (43.93 %) and tablets of 347 items (35.69 %); antibacterial drugs account for the largest share of 677 items (69.65 %); among imported drugs, 316 items (32.51 %) are manufactured in India, in 286 items (29.42 %) are manufactured in Ukraine; according to the international non-proprietary name, mono drugs of 825 items (84.88 %) predominate.

Use of dexmedetomidine in complex treatment of patients in intensive care units

Sedation is an important aspect of adequate treatment of patients in the intensive care unit. Recent drug developments and new ventilation strategies provide improved sedation management that allows for better adaptation to the clinical condition and individual needs of the patient. This article provides an overview of the general principles of sedation of patients in intensive care units and focuses on a relatively new drug in the pharmaceutical market of Ukraine — dexmedetomidine. Given the pandemic of coronavirus disease COVID-19, there was carried out a review of the international and domestic literature describing the use of dexmedetomidine as a sedative and analgesic in patients with acute respiratory distress syndrome caused by SARS-COV-2 virus. Its anti-inflammatory and antioxidant properties are also described, which will allow the use of the drug in complex therapy in the treatment of COVID-19 in severe patients.

The marketing analysis of paracetamol and ibuprofen for the treatment of acute respiratory infections in Ukraine

Aim. To conduct the marketing analysis of medicines registered in Ukraine with the international nonproprietary name (INN) – ibuprofen and paracetamol for the treatment of acute respiratory infections (ARI).
 Materials and methods. The data of the State Register of Medicines of Ukraine, the data of the Register of wholesale and selling prices for medicines in Ukraine as of March 2021 were used. Bibliosemantic, marketing, analytical, graphic, frequency and descriptive analyses were applied.
 Results. The marketing analysis of ibuprofen and paracetamol revealed their different drug forms, namely children’s forms were presented in the form of suspensions, syrups, suppositories, while adults forms – in the form of tablets, capsules, sachets, injectable dosage forms. It was found that ibuprofen was represented at the pharmaceutical market of Ukraine by 10 trade names (TN) in the form of tablets, 5 TN in the form of capsules. 7 TN of Paracetamol were presented in the form of a solution for injection at the pharmaceutical market of Ukraine, 10 TN were in the form of tablets, and 2 TN were in the form of suppositories. The cost of ibuprofen and paracetamol was studied: the cost of 1 package of children’s medicines ranged from 17.2 to 102.31 UAH, ibuprofen – from 16.2 to 150 UAH, paracetamol – from 15.09 to 980 UAH. The most expensive paracetamol was represented by the trade name Parafusiv (paracetamol, 10 mg/ml for inf., 100 ml vial, 10 mg/ml, No.10 (Portugal)).
 Conclusions. The marketing research of ibuprofen and paracetamol has shown their diversity at the pharmaceutical market of Ukraine. These drugs are represented by a wide range of trade names, drug forms, manufacturers and a wide range of prices. The country-manufacturer of all drugs presented is Ukraine (73 %).

Marketing analysis of the domestic pharmaceutical market of antiherpetic medicines

Aim. To conduct the marketing research of the pharmaceutical market of Ukraine in the segment of medicinal products (MP) used for the treatment and prevention of infections caused by HSV-1 and HSV-2.
 Materials and methods. To achieve this aim, methods of logical and meaningful problem formation, desk marketing research, content analysis of publications in scientific and practice-oriented medical and pharmaceutical literature, comparative analysis were used.
 Results. The paper presents the results of the marketing analysis of the Ukrainian pharmaceutical market of antiherpetic MP. For the study, according to the ATC classification, 5 groups of medicines registered at the domestic market were selected. In the drug package leaflets for these medicines herpes infection was one of the indications for use. As of October 1, 2021, the range of antiherpetic MP includes 194 trade names for systemic and local use. The market segmentation of these groups of medicines by manufacturing countries, drug form, conditions of dispensing, origin and composition was carried out. It has been found that the share of herbal medicinal products is 14.43 % (6 positions) and is represented by products for systemic use.
 Conclusions. The research of the market of antiherpetic medicines conducted can be considered as the basis for the search and development of new effective antiviral herbal medicinal products of domestic production for the local treatment of the herpes virus.

A scientific and theoretical approach to the development of the process model for managing personified marketing communications in pharmacy

Aim. To systematize and substantiate the expediency of using personified marketing communications in pharmacy based on a scientific and methodological approach and develop a process model for managing personified marketing communications in pharmacy, which will be useful to pharmaceutical market entities in order to provide the effectiveness of pharmaceutical promotion and interaction with a potential target audience.
 Materials and methods. To implement the objectives, the methods of content analysis, structural and system analysis, sociological and marketing research, comparative analysis, grouping, and graphical method were used.
 Results. The expediency of using personified marketing communications in the system of promoting drugs to the Ukrainian pharmaceutical market has been systematized and substantiated, taking into account the foreign experience. The rating of the activity of using personified marketing communications in Ukraine and abroad has been made and compared; the prospects and advantages of their implementation at the Ukrainian market have been identified. A process model for managing personified marketing communications in pharmacy has been developed and proposed.
 Conclusions. Personified marketing communications provide that the subjects of the pharmaceutical market concentrate their communicative efforts on the target audience; this further gives them the opportunity to save money and minimize unnecessary investment in the promotion of drugs. The proposed process model of management of personified marketing communications in pharmacy will contribute to improving the quality of pharmaceutical care to the country’s population.

Analysis of antiasthmatic drugs for inhalation in the pharmaceutical market of Ukraine and dynamics of their consumption

Bronchial asthma (BA) is a common disease, as today the world suffers from about 300 million people. The number of patients with severe and complicated forms of BA is growing every year due to untimely diagnosis of the disease and late appointment of basic therapy. Complications cause disability in patients and increase mortality.
 The purpose of this work was to study the range and consumption in Ukraine of antiasthmatic drugs for inhalation (ADI), intended for the treatment of BA for the period 2018–2020.
 The analysis of the range and volumes of consumption of ADI was carried out according to the system of research of the market of medicines «Pharmstandard» of the company «Morion». Consumption estimates were made using the ATC/DDD methodology. DDDs/1 000 inhabitants/day (DID, DDDs per 1 000 inhabitants per day) was used as a unit of measurement.
 The results showed that in the pharmaceutical market of Ukraine during 2018–2020 used 61–64 trade names (TN) ADI, of which 11–13 TN were domestically produced and 50–51 TN – foreign manufacturers. Retail prices for ADI during 2018–2020 varied widely and increased slightly each year, due to economic instability in the pharmaceutical market of Ukraine. It was found that the consumption of ADI in the period 2018–2019 increased slightly by 1.03 times – from 7.00 DID in 2018 to 7.24 DID in 2019. In 2020, the consumption of this group of drugs decreased 1.1 times – to 6.60 DID. The undisputed leader in consumption in Ukraine was salbutamol (3.53–3.56 DID), which is probably due to the clinical efficacy and sufficient safety of the drug, greater availability of salbutamol for the population due to the wide range of generic drugs in Ukraine. market and the state program «Affordable Medicines». The second place was taken by the combination of fenoterol + ipratropium bromide (0.81–0.85 DID), which is used in adults and children for the immediate treatment of sudden attacks of bronchospasm in BA. The third place in terms of consumption in Ukraine was occupied by the combination of salmeterol + fluticasone (0.52–0.54 DID), which is mainly prescribed to patients with moderate and severe asthma.

Analysis of the range of drugs for the treatment of arterial hypertension presented on the pharmaceutical market of Ukraine

Analysis of the range of drugs for the treatment of arterial hypertension presented on the pharmaceutical market of Ukraine

Analysis of pharmaceutical market of dietary supplements with green tea leaves extract

The aim of work is to study the assortment of dietary supplements with green tea leaves extract on the modern pharmaceutical market to further search for ways to improve and optimize pharmaceutical supply. Materials and methods. The assortment of dietary supplements with green tea leaves extract was studied basing on the search of dietary supplements in pharmacies of Ukraine in the internet resources. For study of assortment of dietary supplements, the following methods were used: marketing, statistical, logic and graphic. Results. The assortment of dietary supplements with green tea leaves extract has been analyzed. The results showed that the leaders in the number of manufacturers in the analyzed group of dietary supplements are the United States, Ukraine, and Poland, their part is 61 %, 16 % and 8 %, respectively. In terms of assortment, the United States ranks first – 66 %. Dietary supplements are presented in 6 dosage forms, most of them are capsules (60 %). It was determined that monopreparations predominate in the pharmaceutical market and account for 77 %. The price segmentation of the market of dietary supplements with green tea leaves extract has been provided, the results showed that most of these are dietary supplements in the price range of 200–500 UAH. The study of the company structure made it possible to identify leaders among foreign companies; the top three companies included Now Foods (27 %), Swanson (20 %), Puritan’s Pride (14 %). Conclusions. There are 42 dietary supplements with green tea leaves extract at the beginning of 2022 in Ukraine. On the temporary pharmaceutical market of Ukraine 84 % of dietary supplements with green tea extract are presented by foreign manufacturers, mainly by monopreparations, in the form of capsules and in the price range from 200 to 500 UAH.